Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M

Enveric Biosciences, Inc.

2026-Q1 EPS reported -$1.08

Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.
As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.
Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.
AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enveric Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss attributable to stockholders was $1.6 million, EPS basic and diluted loss per share of $1.08.

Period: the first quarter ended March 31, 2026
Net income: Net loss attributable to stockholders was $1.6 million
EPS: basic and diluted loss per share of $1.08
Result: reported results

Exact text from the filing

Net loss attributable to stockholders was $1.6 million for the first quarter ended March 31, 2026, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $1.08

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enveric Biosciences, Inc. reported the quarter ended March 31, 2025 results: net income net loss of $2.2 million, EPS basic and diluted loss per share of $14.58.

Period: the quarter ended March 31, 2025
Net income: net loss of $2.2 million
EPS: basic and diluted loss per share of $14.58
Result: reported results

Exact text from the filing

as compared to a net loss of $2.2 million, including $0.3 million in net non-cash income, with a basic and diluted loss per share of $14.58 for the quarter ended March 31, 2025

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.